|
Distributions of allele frequencies of APOE and STH gene variations in European-American subjects |
||||||||||||||||||
| APOE alleles |
Exact p-values |
STH alleles |
Exact p-values |
|||||||||||||||
|
|
|
|
||||||||||||||||
| ε2 |
ε3 |
ε4 |
Total |
ε2 |
ε3 |
ε4 |
Total |
Q |
R |
Total |
||||||||
|
|
|
|
|
|
||||||||||||||
| f |
n |
f |
n |
f |
n |
2N |
f |
n |
f |
n |
2N |
|||||||
|
|
||||||||||||||||||
| AD |
0.024 |
17 |
0.617 |
443 |
0.359 |
258 |
718 |
0.001 |
6.0*10-12 |
2.4*10-18 |
1.2*10-18 |
0.767 |
439 |
0.233 |
133 |
572 |
0.345 |
1 |
| EOAD |
0.017 |
6 |
0.590 |
203 |
0.392 |
135 |
344 |
0.002 |
4.7*10-11 |
6.8*10-17 |
2.5*10-17 |
0.771 |
216 |
0.229 |
64 |
280 |
0.506 |
2 |
| LOAD |
0.027 |
10 |
0.644 |
237 |
0.329 |
121 |
368 |
0.022 |
3.6*10-7 |
3.1*10-11 |
5.5*10-11 |
0.762 |
218 |
0.238 |
68 |
286 |
0.348 |
2 |
| FH+ |
0.014 |
5 |
0.590 |
204 |
0.396 |
137 |
346 |
6.8*10-4 |
4.9*10-11 |
2.1*10-16 |
2.3*10-17 |
0.737 |
205 |
0.263 |
73 |
278 |
0.094 |
2 |
| FH- |
0.030 |
11 |
0.641 |
232 |
0.329 |
119 |
362 |
0.051 |
2.2*10-7 |
4.1*10-11 |
1.1*10-10 |
0.796 |
226 |
0.204 |
58 |
284 |
1.000 |
2 |
| Male |
0.032 |
9 |
0.635 |
179 |
0.333 |
94 |
282 |
0.093 |
3.9*10-5 |
1.7*10-7 |
3.9*10-7 |
0.738 |
155 |
0.262 |
55 |
210 |
0.145 |
3 |
| Female |
0.018 |
8 |
0.606 |
264 |
0.376 |
164 |
436 |
0.008 |
7.0*10-8 |
9.8*10-12 |
4.9*10-12 |
0.785 |
284 |
0.215 |
78 |
362 |
1.000 |
3 |
| Controls |
0.061 |
30 |
0.801 |
394 |
0.138 |
68 |
492 |
0.794 |
313 |
0.206 |
81 |
394 |
||||||
| Male |
0.065 |
15 |
0.800 |
184 |
0.135 |
31 |
230 |
0.805 |
140 |
0.195 |
34 |
174 |
||||||
| Female |
0.057 |
15 |
0.802 |
210 |
0.141 |
37 |
262 |
0.786 |
173 |
0.214 |
47 |
220 |
||||||
|
f, frequency; n, number of alleles; N, number of individuals; 2N, number of chromosomes; AD, Alzheimer's disease; EOAD, early-onset AD (≤70yrs); LOAD, late-onset AD (>70yrs); Controls, the total controls combining two subgroups through two different diagnostic evaluations. The numbers in last column denote: 1. Comparing overall AD with controls (α was set at 0.017 for each APOE allele comparison); 2. Comparing EOAD, LOAD, FH+AD and FH-AD with controls respectively (α was set at 0.003 for each APOE allele comparison); 3. Comparing male AD with male controls and female AD with female controls (α was set at 0.003 for each APOE allele comparison). | ||||||||||||||||||
Zuo et al. Behavioral and Brain Functions 2006 2:13 doi:10.1186/1744-9081-2-13 |
||||||||||||||||||